No Data
No Data
Jefferies Maintains Addus HomeCare(ADUS.US) With Buy Rating, Raises Target Price to $160
Press Release: Addus HomeCare Announces First Quarter 2025 Earnings Release and Conference Call
Are Investors Undervaluing Addus HomeCare Corporation (NASDAQ:ADUS) By 43%?
Addus HomeCare Is Maintained at Market Outperform by JMP Securities
JMP Securities Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $150
Q4 Rundown: Addus HomeCare (NASDAQ:ADUS) Vs Other Senior Health, Home Health & Hospice Stocks